Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Pharmacogenomics Advisory Committee Will Oversee Data Submissions

Executive Summary

FDA is forming a pharmacogenomics advisory committee to handle voluntary genomic data submissions, Office of Clinical Pharmacology & Biopharmaceutics Director Lawrence Lesko, PhD, said

You may also be interested in...



FDA Ad Warning Letters On Track For Significant Increase In 2005

FDA is on track for a significant increase in the number of warning letters issued to drug marketers for advertising violations in 2005

FDA Ad Warning Letters On Track For Significant Increase In 2005

FDA is on track for a significant increase in the number of warning letters issued to drug marketers for advertising violations in 2005

Biomarker Working Group To Explore Development Of Guidance

An FDA working group will be formed by year-end to consider the development of a guidance on biomarkers

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel